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A rise in cases with a new hyperinflammatory disease in children has been reported
in Europe and in the Unites States of America, named the Pediatric Inflammatory
Multisystem Syndrome—temporally associated with SARS-CoV-2 (PIMS-TS). There
appears to be a wide spectrum of signs and symptoms with varying degrees of
severity, including a toxic shock like presentation with hypovolaemia and shock, and
a Kawasaki-like presentation with involvement of the coronary arteries. Most of these
children have evidence of a previous infection with SARS-CoV-2, or a history of significant
exposure, but not all. Limited data exist on the incidence of PIMS-TS, but it remains
a rare condition. Early recognition and escalation of care is important to prevent
the development of serious sequelae, such as coronary artery aneurysms. Clinicians
assessing febrile children in primary and secondary care should include PIMS-TS in their
differential diagnoses. In children fulfilling the case definition, additional investigations
should be undertaken to look for evidence of inflammation and multiorgan involvement.
Suspected cases should be discussed with experts in pediatric infectious diseases at
an early stage, and advice should be sought from critical care in more severe cases
early. There is limited consensus on treatment; but most children have been treated
with immunoglobulins or steroids, and with early consideration of biologicals such
anti-TNF and anti-IL1 agents. Treatment should ideally be within the context of controlled
treatment trials. Clinicians are encouraged to document and share their cases using
research registries.
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TABLE 1 | Overview of studies reporting children with PIMS-TS.
Population Location Number of
children in study
Number of
settings
Eligibility Date of publication
Riphagen et al. (4) Children with
hyperinflammatory
shock
London, UK 8 1 Admitted to PICU May 6th 2020
Verdoni et al. (5) Children with
Kawasaki-like disease
Bergamo, Italy 10 1 Admitted to the general
pediatric unit
May 13th 2020
Belhadjer et al. (6) Children with acute
heart failure in MIS-C
France,
Switzerland
35 14 Admitted to PICU May 17th 2020
Chiotos et al. (7) Children with MIS-C Philadelphia, US 6 1 Admitted to PICU May 28th 2020
Grimaud et al. (8) Acute myocarditis and
multisystem
inflammatory emerging
disease in critically ill
children
Paris, France 20 4 Admitted to PICU June 1st 2020
Toubiana et al. (9) Children with
Kawasaki-like
multisystem
inflammatory syndrome
Paris, France 21 1 Admitted to general
pediatric ward
June 3rd 2020
Miller et al. (10) Children with MIS-C New York, US 44 1 Admitted to hospital June 4th 2020
Whittaker et al. (11) Children with PIMS-TS United Kingdom 58 8 Admitted to hospital June 8th 2020
Cheung et al. (12) Children with MIS-C New York, US 17 1 Admitted to hospital June 8th 2020
Capone et al. (13) Children with MIS-C New York, US 33 1 Admitted to hospital June 10th 2020
Pouletty et al. (14) Children with PIMS-TS
mimicking Kawasaki
disease
(Kawa-COVID-19)
Paris, France 16 7 Admitted to hospital June 11th 2020
Ramcharan et al. (15) Children with PIMS-TS Birmingham, UK 15 1 Admitted to hospital June 12th 2020
Kaushik et al. (16) Children with MIS-C New York, US 33 3 Admitted to PICU June 14th 2020
Riollano-Cruz et al. (17) Children with MIS-C New York, US 15 1 Admitted to hospital June 25th 2020
Hameed et al. (18) Children with PIMS-TS London, UK 35 1 Admitted to hospital June 25th 2020
Feldstein et al. (19) Children with MIS-C US 186a 53 Admitted to hospital June 29th 2020
Dufort et al. (20) Children with MIS-C New York, US 99b 106 Admitted to hospital June 29th 2020
Overview of articles describing cases of PIMS-TS, SARS-CoV-2 related Kawasaki-like disease, or MIS-C [per 29-06-2020]; only articles with 5 or more cases included.
Search strategy: using MIS-C, PIMS-TS and Kawasaki Disease as search terms in Medline search, age range: 0–<21 years, from April 1st to June 29th 2020; only English articles were
included; only peer reviewed and published articles were included, pre-print manuscripts were excluded.
MISC, Multisystem Inflammatory Syndrome in Children; PICU, Pediatric Intensive Care Unit; PIMS-TS, Pediatric Inflammatory Multisystem Syndrome-temporally associated with
SARS-CoV-2.
aFeldstein et al. (19) excluded cases in the cohort described by Dufort et al. (20) (n = 27), but included cases reported by Chiotos et al. (7) (n = 6) and Waltuch et al. (21) (n = 4).
Feldstein et al. (19): 186 cases meeting the case definition included out of 234 reported cases.
bDufort et al. (20): details of 99 confirmed or suspected cases via Public Health reporting registry included, out of 191 potential reported cases.
STATEMENT
According to the currently available evidence, SARS-CoV-2
infection in children is rarely associated with severe disease (1),
children are less likely to be infected compared with adults,
and children are likely to be less infectious compared with
infective adults (2, 3). However, multiple cases of children with
a new hyperinflammatory condition in children subsequent to
SARS-CoV-2 infection have been reported in Europe and the
United States of America (Tables 1, 2).
Abbreviations: Anti-IL1, anti-Interleukin 1; Anti-IL6, anti-Interleukin 6; Anti-
TNF, anti-Tumor Necrosis Factor; APTT, Activated Partial Thromboplastin Time;
ECG, Electrocardiogram; ESR, Erythrocyte Sedimentation Rate; PCR, Polymerase
Chain Reaction; PT, Prothrombin Time; IL-6, Interleukin-6; PIMS-TS, Pediatric
Inflammatory Multisystem Syndrome-temporally associated with SARS-CoV-2;
pro-BNP, pro-Brain Natriuretic Peptide; SARS-CoV-2, severe acute respiratory
syndrome coronavirus 2.
This statement has been written on behalf of both the Pediatric
Section of the European Society for Emergency Medicine and the
European Academy of Pediatrics to provide an update for health
care professionals in primary or secondary care undertaking
assessments of acutely unwell children. This statement aims to
- provide information about the Pediatric Inflammatory
Multisystem Syndrome temporally associated with
SARS-CoV-2 (PIMS-TS);
- give initial guidance on the clinical assessment and
management of children suspected of this new condition for
health care professionals dealing with acutely unwell children;
- point out useful resources on the recognition andmanagement
of these children.
This statement does not address the management
of children with PIMS-TS admitted under specialist
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TABLE 2 | Presenting signs and symptoms, treatment, and outcomes in children with PIMS-TS.
Whittaker et al. (11) Feldstein et al. (19) Dufort et al. (20)
Age (median, IQR, years) 9 (5.7–14) 8.3 (3.3–12.5) 31 (31%) <5 years,
42 (42%) 6–12 years
Gender, female 33 (57%) 71 (38%) 46 (46%)
Comorbidities 7 (12%) 51 (27%)e 36 (36%)
Overweight, obesitya – 45/153 (29%) 29 (29%)
Asthma 3 (5%) 33 (18%)f 12 (12%)f
Underlying cardiac disease 0 (0%) 5 (3%) –
Clinical signs and symptoms
Fever 58 (100%) 186 (100%) 99 (100%)
Duration of fever/symptoms (median, IQR, in days) 3–9 (range) 6 (5–8) 4 (3–6)
Shockb 29 (50%) 89 (48%) 10 (10%)
Gastro-intestinal symptoms – –g 79 (80%)
Abdominal pain 31 (53%) – 60 (61%)
Diarrhea 30 (52%) – 49 (49%)
Vomiting, nausea 26 (45%) – 57 (58%)
Kawasaki features
Kawasaki, completec 7 (12%) 74 (40%) –j
Rash 30 (52%) 110 (59%) 59 (60%)
Conjunctival injection, conjunctivitis 26 (45%) 103 (55%) 55 (56%)
Mucous membrane changes 17 (29%) 78 (42%) 27 (27%)
(Cervical) lymphadenopathy, >1.5 cm diameter 9 (16%) 18 (10%) 6 (6%)
Swollen hand and feet 9 (16%) 9 (9%)
Changes to extremities – 69 (37%)
Respiratory symptoms 12 (21%) –g 40 (40%)k
Sore throat 6 (10%) – 16 (16%)
Rhinorrhoea, nasal congestion – – 13 (13%)
Chest pain – – 11 (11%)
Neurological symptoms –g 30 (30%)
Confusion, altered mental state 5 (9%) – 2 (2%)
Headaches 15 (26%) – 29 (29%)
Arthralgia, arthritis – 4 (2%) 4 (4%)
Myalgia, myositis – 15 (8%) 17 (17%)
Virology results
Nasopharyngeal SARS-CoV-2 RT-PCR 15 (26%) 73 (56%) 50/98 (51%)
Positive SARS-CoV-2 serology 40/46 (83%) 85 (46%) 76/77 (99%)
No positive SARS-CoV-2 resultd 13 (22%) 55 (30%) 4 (4%)
Immunomodulatory treatment
Nil immunomodulatory drugs 13 (22%) – –
Intravenous immunoglobulins 41 (71%) 144 (77%) 69 (70%)
Steroids 37 (64%) 91 (49%) 63 (64%)
Biologicals
Anakinra (anti-IL1) 3 (5%) 24 (13%) –
Infliximab (anti-TNF-α) 8 (14%) 0 (0%) –
Toculizumab (anti-IL6) 0 (0%) 14 (8%) –
Outcomes
Critical care admission 29 (50%) 148 (80%) 79 (80%)
Inotropic/vasopressor support 27 (47%) 89 (48%) 61 (62%)
(Continued)
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TABLE 2 | Continued
Whittaker et al. (11) Feldstein et al. (19) Dufort et al. (20)
Mechanical invasive ventilation 25 (43%) 37 (20%) 10 (10%)
Extracorporeal membrane oxygenation 3 (5%) 8 (4%) 4 (4%)
Coronary artery aneurysm (z-score >2) 8 (14%) 15 (8%)h 9 (9%)
Deathi 1 (2%) 4 (2%) 2 (2%)
This is a summary table of clinical signs and symptoms, treatment, and outcomes from the three largest cohorts published up until June 29th 2020. Appendix 1 in
Supplementary Materials includes these data from all published cohorts with 10 or more cases (as per June 29th 2020).
IL1, Interleukin 1; IL6, interleukin 6; IQR, Interquartile range; IVIG, intravenous immunoglobulins; RT-PCR, Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2, severe acute
respiratory syndrome coronavirus 2; TNF, Tumor Necrosis Factor.
aFeldstein et al. (19) report both clinically diagnosed obesity (n = 12/153, 8%) and BMI based obesity (n = 45/153, 29%).
bWhittaker et al. (11): shock defined as needing inotrope support or fluid resuscitation >20 mL/kg; Feldstein et al. (19): as requiring vasopressors.
cComplete or classic Kawasaki Disease as defined by fever for ≥5 days plus four or more clinical criteria, including bilateral bulbar non-exudative conjunctivitis, changes of the lips
or oral cavity, non-suppurative laterocervical lymphadenopathy, polymorphic rash, erythema of the palms and soles, firm induration of the hands or feet, or both, as per the American
Heart Association Criteria (22). Whittaker et al. (11): a total of 13 children (22%) met the criteria for Kawasaki Disease when coronary artery aneurysms were included. Feldstein
et al. (19): 74 patients (40%) had fever for at least 5 days and four or five Kawasaki disease–like features or two or three Kawasaki disease–like features plus additional laboratory or
echocardiographic findings.
dPapers also report on epidemiological links with a close contact of suspected or confirmed SARS-CoV-2 contact for those children with negative SARS-CoV-2 diagnostic results.
eFeldstein et al. (19): this is number of children with one or more comorbidities, excluding obesity; other papers included obesity as comorbidity.
fFeldstein et al. (19): number of children with asthma included all children with respiratory comorbidity; Dufort et al. (20): additional 2 children had other respiratory comorbidities.
gFeldstein et al. (19): showed gastro-intestinal involvement in 170 (91%) children, respiratory insufficiency or failure in 109 (59%) children, and neurological complications (encephalitis,
aseptic meningitis, demyelinating disorder, seizures, coma or unresponsive within 24 h of admission) in 10 (6%) children; 132 (71%) children had four or more organ systems involved,
36 (19%) children had three organ systems involved, 18 (10%) children had two organ systems involved.
hFeldstein et al. (19): z-score >2.5.
iNot all children had been discharged from hospital at the end of the study periods.
jDufort et al. (20): a total of 36 patients (36%) received a diagnosis of Kawasaki Disease or atypical (or incomplete) Kawasaki Disease.
kDufort et al. (20): including cough n = 31 (31%), shortness of breath n = 19 (19%), wheezing n = 1 (1%).
care in the fields of infectious diseases, cardiology, or
critical care.
Historically, a link between coronaviruses and Kawasaki
syndrome was first proposed in 2005 (23). However, a causal
relation has thus far not been proven, and the cause of
Kawasaki Disease is currently unknown (24, 25). Awareness of
the new hyperinflammatory condition affecting children was
raised by clinicians in the UK, leading to an alert by the UK
National Health Service, on April 25th 2020. Since then many
other countries have issued similar alerts with guidance on
management of these children. The first case report of a child
with Kawasaki-like disease was reported in the international
literature on April 22nd (26). The first case series with cases from
the UK was reported on May 7th (5), followed by similar case
series from Italy on May 13th [9]. Cases have now been reported
throughout Europe and North America, with the European
Center for Disease Control providing an up to date overview (27).
The European Society for Medicine and the European Academy
of Pediatrics hosted informative webinars (links in Table 3).
The initial guidance from the Royal College of Pediatrics
and Child Health in the United Kingdom provided a case
definition and called this emerging disease entity the Pediatric
Inflammatory Multisystem Syndrome—temporally associated
with SARS-CoV-2 (PIMS-TS) (28). In the United States
this disorder is referred to as the multisystem inflammatory
syndrome in children (MIS-C) (29). By now, three case
definitions are in use (Table 4). We recommend adhering to the
case definition by the World Health Organization, as at present
this definition appears to capture the spectrum of presenting
signs and symptoms best (30). All current bodies proposing case
definitions acknowledge the rapidly developing evidence and the
need for continued evolvement of the case definitions.
The three case definitions have in common that they describe
a population of children at risk with (1) persistent fever,
(2) clinical signs and biochemical profiles reflecting ongoing
inflammation, (3) the potential of multiorgan involvement (and
most importantly the risk of cardiac involvement), (4) the
absence of other reasonable explanations of the acute illness, and
(5) evidence of a preceding SARS-CoV-2 infection or exposure
to a suspected or confirmed case. Notably, children of all ages
appear affected, but it has been more commonly reported in
the adolescent age group, which is distinctly different from the
children with classic Kawasaki Disease and children with toxic
shock syndrome (5, 11). Also, boys and girls appear affected
similarly (Table 2, Appendix 1 in Supplementary Materials),
whereas children of black and minority ethnicity backgrounds
appear affected more often (4, 9, 11).
It is important to stress that the incidence of PIMS-TS is
rare with an estimated incidence at 2 in 100,000 persons <21
years of age (20). Also, although some deaths in children with
PIMS-TS have been reported, as well as children requiring extra-
corporeal membrane oxygenation (27), many affected children
don’t require critical care and have a full, and rapid clinical
recovery (Table 2, Appendix 1 in Supplementary Materials).
There appears to be a wide spectrum of signs and symptoms
with varying degree of severity (Table 2, Appendix 1 in
Supplementary Materials). All children present with persistent
fever. Typically, a substantial proportion of children present
with abdominal symptoms, with some having symptoms of such
severity that they had US and CT imaging, and some undergoing
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TABLE 3 | Available resources, guidelines and ongoing studies.
Resources and guidelines
European Center for Disease Prevention and Control (ECDC)
https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-SARS-CoV-2-rapid-risk-assessment
British Pediatric Allergy, Immunity and infection Group (UK)
https://www.bpaiig.org/news-bpaiig-position-statement-SARS-CoV-2-treatment-guidance-version-12
Royal College of Pediatrics and Child Health (UK)
https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19
Don’t forget the bubbles
https://dontforgetthebubbles.com/pims-ts/
World Health organization (WHO)
https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
American Academy of Pediatrics (US)
https://www.aappublications.org/news/2020/05/14/covid19inflammatory051420?cct=2287
Center of Disease Control and prevention (US)
https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html#anchor_1589580133375
https://emergency.cdc.gov/han/2020/han00432.asp
PENTA network
https://penta-id.org/covid-19-outbreak/
European Society of Medicine
https://eusem.org/news/corona-virus
European Academy of Pediatrics
https://www.eapaediatrics.eu/covid-19-resource-centre/
PIMS-TS studies and registries
Clinical data collection:
ISARIC study, International Severe Acute Respiratory and emerging Infection Consortium: https://isaric.tghn.org
British Pediatric Surveillance Unit (UK)
https://www.rcpch.ac.uk/work-we-do/bpsu/study-multisystem-inflammatory-syndrome-kawasaki-disease-toxic-shock-syndrome
World Health organization (WHO)
https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
Diagnostics and -omics studies:
DIAMONDS study, Diagnosis and Management of Febrile Illness using RNA Personalized Molecular Signature Diagnosis (Europe):
https://www.diamonds2020.eu
Treatment studies:
Registry: Best Available Treatment Study for the Pediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (BATS-study):
https://bestavailabletreatmentstudy.co.uk
Clinical trial: RECOVERY trial, Randomized Evaluation of COVID-19 Therapy:
https://www.recoverytrial.net
surgical procedures (10, 11, 31). The PIMS-TS spectrum includes
disease entities that need urgent recognition and treatment,
such as a toxic shock like presentation with hypovolaemia and
shock, as well as Kawasaki-like disease with involvement of
the coronary arteries (4–6). Children with Kawasaki-like disease
will have all or some of the typical features, such as a rash
and skin changes, conjunctival injection, mucous membrane
changes, unilateral lymphadenopathy, and swollen hands and
feet (6, 11). A majority of the reported children with PIMS-
TS had evidence of multiorgan involvement (19). A number
of these children will subsequently need critical care with
(multiorgan) supportive care, whereas others can be managed
safely on normal pediatric wards. Almost exclusively, these
children appear ill and present in a manner that warrants enough
concern to admit them to hospital and to perform additional
diagnostic tests. By now, it appears that the biochemical
profile of children with PIMS-TS is distinct from that of
children with classic Kawasaki Disease and Kawasaki Disease
with shock, with children with PIMS-TS having noticeably
higher markers of inflammation (e.g., CRP, ferritin), marked
lymfopaenia, greater elevation of troponin, and higher levels
of fibrinogen; it is less clear how the biochemical profiles
differ from children with toxic shock syndrome (11). Lastly,
it is important to note, however, that the cases reported in
the literature are likely to represent the more severe spectrum
of disease.
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TABLE 4 | Case definitions of PIMS-TS (or MIS-C).
Population Clinical signs and
symptoms
Evidence of
multiorgan
involvement
Markers of
inflammation
Evidence of other
infections
Evidence of
SARS-CoV-2
infection
Additional comments
World Health
Organization (30)
Children and
adolescents
0–19 years of
age
Fever > 3 days
And two of the
following:∧
Rash or bilateral
non-purulent
conjunctivitis or
muco-cutaneous
inflammation signs
(oral, hands, or feet).
Hypotension or shock.
Acute gastrointestinal
problems (diarrhea,
vomiting, or
abdominal pain)
Features of myocardial
dysfunction,
pericarditis, valvulitis, or
coronary abnormalities,
including
echocardiogram
findings or elevated
Troponin/NT-proBNP
Evidence of
coagulopathy (by PT,
APTT,
elevated d-Dimers)
Elevated markers of
inflammation such as
erythrocyte
sedimentation rate,
C-reactive protein, or
procalcitonin
No other obvious
microbial cause of
inflammation, including
bacterial sepsis,
staphylococcal, or
streptococcal shock
syndromes
Evidence of COVID-19
(RT-PCR, antigen test,
or serology positive), or
likely contact with
patients with COVID-19
Center of Disease
Control and
Prevention (CDC)
(US) (29)
An individual
under 21
years
Presenting with fever
The CDC note the fever
should be at least 38
degrees Celsius for at
least 24 h or a
subjective fever
lasting 24 h
Evidence of clinically
severe illness requiring
hospitalization with
multisystem (>2) organ
involvement (cardiac,
renal, respiratory,
hematologic,
gastrointestinal,
dermatologic, or
neurological)
Evidence of
inflammation could
include but is not
limited to an elevated
C-reactive protein,
erythrocyte
sedimentation rate,
fibrinogen,
procalcitonin, d-dimer,
ferritin, lactic acid
dehydrogenase, or
interleukin 6, elevated
neutrophils, reduced
lymphocytes, and low
albumin
No alternative plausible
diagnoses
Positive for current or
recent SARS-CoV-2
infection by
reverse-transcriptase
polymerase chain
reaction, serology or
antigen test; or
COVID-19 exposure
within the 4 weeks prior
to the onset of
symptoms
Some individuals may
fulfill full or partial
criteria for Kawasaki
disease but should be
reported if they meet
the case definition for
MIS-C
Consider MIS-C in any
pediatric death with
evidence of
SARS-CoV-2 infection
Royal College of
Pediatrics and
Child Health (UK)
(28)
Any child Persistent fever Evidence of single or
multi-organ dysfunction
(shock, cardiac,
respiratory, renal,
gastrointestinal or
neurological disorder)
with other additional
clinical, laboratory or
imagining, and ECG
features
Neutrophilia, elevated
CRP, and
lymphopaenia
Exclusion of any other
microbial cause,
including bacterial
sepsis, staphylococcal
or streptococcal shock
syndromes, infections
associated with
myocarditis such as
enterovirus
SARS-CoV-2 PCR
testing positive or
negative
Children fulfilling full or
partial criteria for
Kawasaki disease may
be included
∧Two of the following of clinical signs and symptoms, or evidence of multiorgan involvement.
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Some of these children test positive for SARS-CoV-2
on PCR, and most have evidence of a previous infection
with positive SARS-CoV-2 serology (Table 2, Appendix 1 in
Supplementary Materials); however, some cases do not have
a history of exposure to SARS-CoV-2 and do not have clear
evidence of a (previous) SARS-CoV-2 infection (11). It remains
important to perform (serial) tests to confirm the presence
of active or previous infection with SARS-CoV-2, and to
further our understanding of the relationship between and
the underlying mechanisms of infection with SARS-CoV-2 and
PIMS-TS (32).
After a reduction in the number of presentations to emergency
departments during the lockdown periods across Europe (33),
the raised awareness of PIMS-TS in the media might lead to
an increase of presentations of children with fever and other
infectious symptoms to acute care facilities. Public health bodies
should communicate clearly with the general public about the
warning signs of PIMS-TS and about when to seek care as to
prevent delayed presentations (34, 35). Moreover, an increase in
incidence of PIMS-TS has a 4–6 weeks delay after the onset of a
COVID-19 outbreak (19, 20, 36).
As with any emerging disease, it might not immediately be
straightforward deciding who is at risk of PIMS-TS, and in
whom to perform additional investigations. This could adversely
lead to false positive test results creating clinical uncertainty,
erroneous clinical decision making, and heightened parental
anxiety. Similarly, there is a risk that children will be classified
as having sepsis, exacerbated by the risk of delayed presentations
during a pandemic (34), and that they will be managed as such
in their local hospital, without appropriate investigations and
escalation of care. There is also a risk that many children with
other, more common, childhood infections will be classified as
suspected PIMS-TS and will undergo unnecessary diagnostic
tests and treatment. For children with abdominal symptoms, an
early diagnosis of PIMS-TS may inadvertently lead to a delay in
surgical review, and concerns of surgical abdominal pathology
could inversely lead to a delay in recognition of a diagnosis
of PIMS-TS. Involvement of senior clinical decision makers
and adherence to up-to-date case definitions and guidance
are advisable.
Altogether, the emergence of PIMS-TS dictates careful clinical
decision making when dealing with febrile children presenting to
acute care facilities across Europe:
1. The need for additional investigations should be based on
the initial clinical assessment of a febrile child by a clinician
experienced in pediatric care.
2. The management of febrile children who appear clinically
well, with a clear focus of infection, and who would previously
have been deemed well enough for discharge from our care
without any interventions should generally not change; this is
likely to reflect the management of the vast majority of febrile
children presenting to acute care facilities.
3. Ensure that the presence or absence of all Kawasaki-like
features are documented for all febrile children; ensure
that a blood pressure and a full set of vital parameters
are recorded.
4. Clinicians should be aware of and follow published guidance
on PIMS-TS by (inter)national societies (Table 3).
5. Perform additional investigations at an early stage in unwell
appearing febrile children with sufficient heightened clinical
concern as based on the case definition, or with clinical signs
of inflammation and/or shock.
6. Additional laboratory investigations should include markers
of myocardial involvement (such as troponin, pro-BNP),
hypercoagulation (including APTT, PT, fibrinogen, D-Dimer),
markers of inflammation (such as C-reactive protein,
procalcitonin, ferritin, IL-6, erythrocyte sedimentation rate),
creatine kinase, lactate dehydrogenase, full blood count, renal
profile, vitamin D level, and liver function tests, including
triglycerides; include amylase in the presence of abdominal
symptoms (Table 5).
7. Request appropriate microbiology, including a blood culture,
and virology tests to rule out any other infectious cause of
the illness (Table 5). We also suggest PCR of oropharyngeal
swab for SARS-CoV-2 in first instance. Save an EDTA and
TABLE 5 | List of investigations in PIMS-TS.
Blood tests Blood gas with lactate
Full blood count and film
Renal profile
Liver function tests, LDH, Triglycerides, CK
Amylase in presence of abdominal symptoms
C-reactive protein, procalcitonin, ferritin, ESR
Coagulation screen with fibrinogen and
D-Dimer
Troponin, pro-BNP
Vitamin D
Imaging Chest X ray
ECG, echocardiogram
Abdominal US with abdominal symptoms
Microbiology and virology Blood culture
Urine culture
Stools culture
Throat culture
Nasopharyngeal aspirate or throat swab for
PCR for respiratory viruses
Mycoplasma pneumoniae titres, ASOT
PCR for bacterial pathogens (e.g.,
meningococcal, pneumococcal, streptococcal,
and staphylococcal PCR) on blood
PCR for EBV, CMV, adenovirus, parvovirus,
enterovirus, and parechovirus on blood
HIV
Save samples for PCR and serology studies
(prior to IVIG)
SARS-CoV-2 investigations SARS-CoV-2 Respiratory PCR; Consider PCR
on stools and blood
SARS-CoV-2 serology
Proposed list of initial investigations in children with suspected PIMS-TS needing hospital
admission. This list is not exhaustive and additional investigations should be tailored to
each individual patient.
Anti-Streptolysin O Titer; CK, Creatine Kinase; EBV, Epstein-Barr Virus; ECG,
electrocardiogram; ESR, Erythrocyte Sedimentation Rate; HIV, Human Immunodeficiency
Virus; LDH, lactate dehydrogenase; PCR, Polymerase Chain Reaction; pro-BNP, pro-
Brain Natriuretic Peptide; SARS-CoV-2, severe acute respiratory syndrome coronavirus
2; US, Ultrasound.
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serum sample for PCR and serology studies prior to giving
intravenous immunoglobulins.
8. An ECG and echocardiogram should be part of the diagnostic
work-up of all children with suspected PIMS-TS.
9. We recommend early discussion with a specialist pediatric
infectious diseases team if there is clinical and biochemical
evidence of inflammation and suspicion of PIMS-TS. We
also recommend early discussion with a pediatric critical
care team in children in need for single or multiple
organ support. Any evidence of myocardial involvement (for
example, raised troponin or pro-BNP, or concerning ECG or
echocardiogram) warrants early escalation to a center with
pediatric cardiology expertise.
This statement does not cover the specific treatment of individual
children with PIMS-TS; all these children should be discussed
with a pediatric expertise center. At present, there is no high-level
evidence to support any best care recommendations about the
treatment of these children outside providing optimal supportive
care. For children with Kawasaki-like disease, the mainstay of
treatment consists of intravenous immunoglobulins, steroids
and possibly additional biologicals, such as anti-TNF, anti-IL1,
or anti-IL6, and aspirin. For children presenting with a toxic
shock like picture, treatment should focus on early cardiovascular
support, treatment and reversal of shock, and intravenous
immunoglobulins. Fluid boluses should be titrated carefully
in view of the risk of myocardial impairment; inotropes and
vasopressors should be started early as per established advanced
life support guidelines (37). Another clinical picture describing
patients with both Kawasaki-like disease plus shock will need
aggressive treatment for both. Standards of antimicrobial
stewardship should be upheld, but it will be difficult to withhold
broad spectrum antibiotics as part of initial emergency care
in most instances, and secondary bacterial infections have
been reported. Additionally, many of these children will have
evidence of hypercoagulation, and prophylactic or therapeutic
anti-coagulation should be considered early in all children with
PIMS-TS. It is crucial to highlight that treatment is time critical
and should not be delayed. Immunomodulatory treatments
should ideally be given in the context of a controlled trial,
but it might prove difficult to set up and enroll children in
randomized controlled trials for the treatment of PIMS-TS in the
near future. The UK RECOVERY trial (Randomized Evaluation
of COVID-19 Therapy) is currently the largest randomized
controlled trial including children (38). Other international
registries are aiming to capture clinical data (e.g. ISARIC study)
and the use of different treatments (e.g. BATS study) around the
world (Table 3).
A concern of the treatment with immunoglobulins, or
convalescent plasma, is the unexplored potential to trigger an
antibody mediated response, similar to the one that potentially
underlies this hyperinflammatory syndrome.
Recommendations for the intermediate and long-term
follow-up of children with PIMS-TS after hospitals discharge
should be guided by the tertiary specialty teams. Special
consideration should be given to the need of performing
post-discharge echocardiograms to exclude late cardiac
complications (15).
RECOMMENDATIONS BY THE PEDIATRIC
SECTION OF THE EUROPEAN SOCIETY
OF EMERGENCY MEDICINE AND THE
EUROPEAN ACADEMY OF PEDIATRICS
1. Parents should seek medical attention if their child is unwell,
develops any warning signs of fever as described by the traffic
light system by the National Institute of Health and Care
Excellence, or has a persistent fever for more than 5 days, to
avoid delayed presentation (39).
2. Health care professionals in primary and secondary care
looking after acutely unwell children are urged to take
notice of the emerging PIMS-TS (Pediatric Inflammatory
Multisystem Syndrome—temporally associated with SARS-
CoV-2) and to be vigilant, as serious sequelae might occur if
not recognized and treated in a timely manner.
3. We recommend performing additional investigations as per
published guidelines (Table 5) and to refer patients with
severe manifestations to specialist centers.
4. Children with PIMS-TS appear to respond well to treatment if
recognized promptly with no delay in treatment, and most of
the children will have a full and quick recovery. Thus, we urge
all primary and secondary care health care professionals to
include the diagnosis of PIMS-TS in the differential diagnosis
of children with persistent fever for more than 5 days.
5. We recommend that clinicians document and share the data
of their patients using research registries (Table 3) to study
the full clinical spectrum of presenting signs and symptoms,
ascertaining biochemical profiles of these children, validate
predictors of disease progression, and to monitor treatment
response (40).
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